Creating genetic resistance to HIV.

PubWeight™: 0.93‹?›

🔗 View Article (PMC 3478429)

Published in Curr Opin Immunol on September 15, 2012

Authors

John C Burnett1, John A Zaia, John J Rossi

Author Affiliations

1: Beckman Research Institute of the City of Hope, Duarte, CA, USA.

Associated clinical trials:

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger) | NCT00842634

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients | NCT01044654

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects | NCT01252641

A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial (Rollover) | NCT00622232

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T | NCT01543152

An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection | NCT00074997

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV | NCT00131560

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial | NCT01177059

High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT | NCT00858793

Articles cited by this

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99

Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol (2009) 4.48

Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23

Gene therapy. Intracellular immunization. Nature (1988) 3.60

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS (2010) 2.94

HIV-1 proviral DNA excision using an evolved recombinase. Science (2007) 2.81

HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21

Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17

Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14

Knockdown screens to knockout HIV-1. Cell (2008) 1.73

Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest (2009) 1.73

Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood (2008) 1.51

Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50

Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest (2010) 1.49

Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44

Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43

A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood (1999) 1.41

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 1.37

Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol (2003) 1.34

Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell (2012) 1.33

Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27

Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One (2011) 1.21

Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19

Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol (2006) 1.12

Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol (2012) 1.12

Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med (2005) 1.11

Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput Biol (2011) 1.10

Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther (2012) 1.10

Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS (2011) 1.09

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther (1998) 1.09

HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe (2008) 1.07

Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05

Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther (2010) 1.03

Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther (2009) 1.03

HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther (2012) 1.01

Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol (2005) 1.01

Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum Gene Ther (2008) 1.01

Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99

Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology (2000) 0.97

Ribozyme therapy for HIV infection. Adv Drug Deliv Rev (2000) 0.95

Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92

N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination. J Virol (2011) 0.91

Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol (2009) 0.90

Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS One (2012) 0.89

Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Mol Ther (2012) 0.88

Long-term regulation of genetically modified primary hematopoietic cells in dogs. Mol Ther (2011) 0.88

In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology (2010) 0.86

Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol (1997) 0.86

Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res (2010) 0.86

Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy. Hum Gene Ther (2012) 0.86

Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol (2010) 0.85

Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter. Hum Gene Ther (2010) 0.84

Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther (2011) 0.83

Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages. Hum Gene Ther (2011) 0.82

A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther (1999) 0.81

Strategies in designing multigene expression units to downregulate HIV-1. Methods Mol Biol (2010) 0.80

APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication. Retrovirology (2008) 0.78

Articles by these authors

The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53

Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40

Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19

Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93

MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92

Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91

MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16

TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05

Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53

The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14

RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13

RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01

Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83

Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76

MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73

Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62

Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48

Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17

SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08

Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02

An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther (2005) 1.89

Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82

RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80

Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78

Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75

Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74

Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64

Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64

siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (2005) 1.60

RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59

Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther (2013) 1.49

Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood (2010) 1.47

Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44

Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42

Functional siRNA expression from transfected PCR products. RNA (2002) 1.42

Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40

Lack of association of cytomegalovirus with human brain tumors. Mod Pathol (2005) 1.40

De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40

A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39

CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A (2009) 1.38

HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res (2005) 1.37

Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36

Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR. Nucleic Acids Res (2009) 1.35

Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34

A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34

Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34

A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther (2007) 1.34

Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31

Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther (2003) 1.29

RNAi and the P-body connection. Nat Cell Biol (2005) 1.29

Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28

TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27

A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res (2008) 1.25

Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21

Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21

Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol (2003) 1.20

Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19

A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17

Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17

Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17

Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16

Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood (2009) 1.14

Expressing short hairpin RNAs in vivo. Nat Methods (2006) 1.14

Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12

A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res (2010) 1.11

Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10

Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10

Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther (2003) 1.10

Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther (2007) 1.08

In vivo evidence insufficient to conclude that "KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission". Blood (2013) 1.08

Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07

Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07

Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07

Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor. Front Immunol (2013) 1.06

Control of HIV-1 replication by RNA interference. Virus Res (2004) 1.05

Amplification of RNAi--targeting HLA mRNAs. Mol Ther (2005) 1.05

Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev (2003) 1.04

Uncoupling of RNAi from active translation in mammalian cells. RNA (2004) 1.04

Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One (2012) 1.04

RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 1.03

Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol (2005) 1.03

Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02

The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem (2009) 0.99

Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99

Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers. J Virol (2007) 0.98

Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis (2006) 0.98

Epigenetics and microRNAs. Pediatr Res (2007) 0.98